Movalis how many ampoules in a package. Movalis injections. Use in the elderly

Movalis is a drug of the group of non-steroidal anti-inflammatory drugs (NSAIDs), which have analgesic, antipyretic, anti-inflammatory effects.

The main active ingredient is meloxicam, a non-steroidal anti-inflammatory drug, a selective inhibitor of cyclooxygenase-2. Its pronounced anti-inflammatory, analgesic effect is observed in all models of inflammatory processes.

This directed action of Movalis is associated with a more selective suppression of COX-2 than COX-1. Inhibition of COX-2 determines the therapeutic effect of NSAIDs, and the suppression of the COX-1 isoenzyme, which is constantly present in the body, is responsible for the negative effects on the kidneys and stomach that are characteristic of this group of drugs.

The selective effect of Movalis on COX-2 has been repeatedly confirmed both in test systems and on living organisms. Unlike popular drugs such as indomethacin, ibuprofen, naproxen, and diclofenac, therapeutic doses of meloxicam do not increase platelet aggregation or prolong the bleeding period.

In clinical studies, adverse reactions from the gastrointestinal tract were generally observed less frequently when taking Movalis 7.5 and 15 mg than when using other NSAIDs taken for comparison. This difference in the incidence of side effects from the gastrointestinal tract in practice is manifested by a more rare occurrence of symptoms such as abdominal pain, nausea, vomiting, dyspepsia.

The frequency of bleeding, ulcers and perforations in the upper gastrointestinal tract, which are presumably associated with the use of meloxicam, is low and is determined by the dosage.

Available in the following dosage forms:

Tablets: from pale yellow to yellow, on the one hand - a concave risk and a code, on the other (convex with a beveled edge) - the manufacturer's logo, surface roughness is allowed (in blisters of 10 pcs., 1 or 2 blisters in a carton box );
Suspension for oral administration: viscous, yellowish with a green tint (in dark glass bottles of 100 ml, 1 bottle in a cardboard box, complete with a dosing spoon);
Solution for intramuscular injection: transparent, yellow with a green tint (in colorless glass ampoules of 1.5 ml, 3 or 5 ampoules in blister packs or trays, 1 or 2 packs or trays in a carton box);
Rectal suppositories: yellowish-green, smooth, at the base - a recess (in blister packs of 6 pcs., 1 or 2 packs in a carton box).

The bioavailability of the drug, regardless of the form of release, is practically the same, but the fastest effect of the drug can be obtained when using ampoules for intravenous or intramuscular administration. The process of drug metabolism occurs in the liver. The drug is excreted from the body in ~ 20 hours after application.

Indications for use

What helps Movalis? The drug is prescribed in the following cases:

Initial treatment of pain and symptomatic therapy of arthritis (rheumatoid), ankylosing spondylitis, osteoarthritis with a short regimen.
Other diseases of the musculoskeletal system of a degenerative and inflammatory nature, accompanied by pain: dorsopathy, arthropathy.

Tablets and suppositories:

Symptomatic therapy of osteoarthritis, ankylosing spondylitis and rheumatoid arthritis and other pathologies of the musculoskeletal system associated with a pain symptom.

Instructions for use Movalis, dosage

injections

Intramuscular administration is indicated only during the first 2-3 days of treatment. In the future, therapy is continued with the use of enteral forms.

The maximum recommended daily dose is 15 mg.

The drug is administered by deep intramuscular injection. Given the possible incompatibility, the contents of the ampoules should not be mixed in the same syringe with other drugs.

Intravenous administration is not allowed!

Tablets and suppositories

Standard dosages:

Osteoarthritis, rheumatoid arthritis - 7.5 mg per day. If necessary, this dose can be increased to 15 mg per day. Depending on the therapeutic effect, this dose can be reduced to 7.5 mg per day.
Ankylosing spondylitis - 15 mg per day. Depending on the therapeutic effect, this dose can be reduced to 7.5 mg per day.
In patients with an increased risk of adverse reactions, it is recommended to start treatment with a dose of 7.5 mg per day. For patients with severe renal insufficiency on hemodialysis, the dose should not exceed 7.5 mg per day.

Syrup

The syrup is taken orally at a dosage of 7.5 mg. This volume corresponds to filling 1 measuring spoon. If required, drink 2 tablespoons of the medicine at a time per day. The dosage is prescribed to patients with spondylitis or rheumatoid arthritis, with improvement it is reduced to 7.5 mg.

It is necessary to drink the drug with meals. The maximum volume is 2 spoons. In juvenile arthritis, Movalis syrup is given to children under 12 years of age based on their weight - 0.125 mg / kg. You can drink 1 time per knock.

The maximum dose for children is 7.5 mg. After 12 years, the amount of suspension is calculated according to the formula: 0.25 mg per kg of body weight per day.

Side effects

The appointment of Movalis may be accompanied by the following side effects:

anemia, changes in the parameters of the general blood test;
dizziness, disorientation, sudden mood swings, drowsiness, fatigue;
bleeding in the stomach or intestines (sometimes fatal), stomatitis, severe abdominal pain, stool disorders, bloating, changes in liver parameters (elevated bilirubin, which may indicate the course of hepatitis);
allergic reactions (anaphylactic shock, urticaria, rashes on the skin, itching, erythema);
the likelihood of developing bronchial asthma is high;
swelling of the face, increased blood pressure, palpitations;
the occurrence of serious pathologies of the kidneys, serious deviations in the indicators of kidney function, urinary retention, painful urination;
blurred vision, conjunctivitis.

Contraindications

Movalis is contraindicated in the following cases:

The combination of bronchial asthma (complete or partial), recurrent polyposis of the paranasal sinuses and nose with intolerance to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (currently or a history of indications);
Peptic ulcer and / or perforation of the stomach and duodenum (with exacerbation or recently transferred);
Active gastrointestinal bleeding; recent cerebrovascular bleeding or confirmed diseases of the blood coagulation system;
Crohn's disease or ulcerative colitis (with exacerbation);
Progressive kidney disease, severe renal failure (with confirmed hyperkalemia; with creatinine clearance less than 30 ml per minute; in cases where hemodialysis is not performed);
Liver failure in severe form;
Uncontrolled severe heart failure;
Postoperative pain associated with coronary artery bypass surgery;
Rare hereditary galactose intolerance (when prescribing the drug in the form of tablets (the maximum daily dose of Movalis 7.5/15 mg, respectively, includes 47/20 mg of lactose));
Rare hereditary fructose intolerance (when prescribing the drug in the form of a suspension for oral administration (the maximum daily dose of the drug includes 2450 mg of sorbitol));
Age up to 18 years (when prescribing the drug in the form of an injection solution); up to 12 years (when prescribing the drug in the form of tablets, oral suspensions, suppositories, with the exception of the use of Movalis in the treatment of juvenile rheumatoid arthritis);
Pregnancy and the period of breastfeeding;
Hypersensitivity to the components of the drug, as well as to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs (there is a possibility of developing cross-hypersensitivity).

Overdose

When using NSAIDs, patients with diseases of the digestive tract should regularly monitor their condition with a doctor. In the event of gastrointestinal bleeding, the drug should be immediately discontinued.

It is also necessary to stop treatment with a significant increase in the activity of transaminases or other indicators of liver function.

Movalis analogues, price in pharmacies

If necessary, you can replace Movalis with an analogue of the active substance - these are drugs:

Artrozan,
Amelotex,
Meloxicam,
Movasin,
Melbek,
Liberum,
bi-xcam,
Mesipol.

When choosing analogues, it is important to understand that the instructions for use of Movalis, the price and reviews of drugs of similar action do not apply. It is important to consult a doctor and not to make an independent replacement of the drug.

Prices in Moscow pharmacies: Movalis tablets 15 mg 10 pcs. - 496 rubles, 7.5 mg 20 pcs. - 609 rubles, solution 15 mg / 1.5 ml 1.5 ml 3 pcs. - 623 rubles.

Store in a dry, protected from light, at a temperature not exceeding 30 C. Shelf life 3 years.

Ksefokam or Movalis - which is better?

Xefocam gives a more pronounced analgesic result, but more often causes side effects. For problems with the gastrointestinal tract, it is recommended to choose a more gentle drug - Movalis, which is better tolerated by patients and is quite effective in inflammatory processes.

Movalis is a non-steroidal anti-inflammatory drug (NSAID), which, when administered, has analgesic, antipyretic and anti-inflammatory effects.

Injections are often prescribed at the very beginning of treatment, when the inflammatory and pain syndrome is more pronounced. After alleviating the patient's condition, therapy is continued with the help of rectal suppositories or oral tablets, the duration of the course of treatment is determined by the doctor.

In this article, we will consider why doctors prescribe Movalis, including instructions for use, analogues and prices for this drug in pharmacies. If you have already used Movalis, leave your feedback in the comments.

Composition and form of release

The drug Movalis (active ingredient - meloxicam) is available in the following forms:

Tablets with a dosage of 7.5 or 15 mg. They have a pale yellow color, a round shape, as well as an engraving of the manufacturer's logo and the content of meloxicam ("59D" - 7.5 mg, "77C" - 15 mg). Packed in blisters of 10 pieces and cardboard boxes containing 10 or 20 tablets.
Suspension for internal use- a viscous liquid with a yellow-green tint. 5 ml of suspension contains 7.5 mg of meloxicam. Produced in dark glass bottles. There is a measuring spoon in the box.
Solution for injection, for intramuscular injections- transparent liquid with a slight yellow-green tint. Produced in glass ampoules with a volume of 1.5 ml, 3 and 5 pieces, placed in plastic pallets and cardboard packaging. Each ampoule contains 15 mg of meloxicam.

Clinical and pharmacological group: NSAIDs.

What is Movalis used for?

The main active substance of the drug, meloxicam, suppresses the inflammatory processes occurring in the body, and also largely relieves the sensation of pain, which makes Movalis effective in a number of diseases, such as:

rheumatoid arthritis;
osteoarthritis;
Bechterew's disease (ankylosing spondylitis);
with pain syndromes in the joints and spine (sciatica, osteochondrosis, etc.).

The use of Movalis in osteochondrosis of the lumbar or cervical regions has practically no restrictions (except in special cases). At the same time, it is important that the drug, unlike its analogues, does not have a negative effect on cartilage tissue, and the analgesic effect appears after half an hour and lasts about a day.

pharmachologic effect

MOVALIS is a non-steroidal anti-inflammatory drug (NSAID) from the group of oxycams, which has anti-inflammatory, analgesic and antipyretic effects. The anti-inflammatory effect of meloxicam has been established in all standard models of inflammation.

The mechanism of action of meloxicam is its ability to inhibit the synthesis of prostaglandins, known inflammatory mediators.

Instructions for use

Movalis solution for intramuscular injection:

The recommended daily dose is 7.5 mg or 15 mg (maximum), the frequency of use is 1 time per day. The dose is determined by the severity of the inflammatory process and the intensity of pain.

The injection solution must be administered deep intramuscularly (intravenous use is contraindicated). Movalis should not be mixed with other drugs in the same syringe. Intramuscular administration of Movalis is usually prescribed only during the first 2-3 days of therapy, after which they switch to the use of enteral forms of the drug.

Depending on the disease, the dosage of the tablets may have some differences:

Ankylosing spondylitis: prescribed at the rate of 15 mg / day. When a therapeutic effect is achieved, the dose can be reduced to 7.5 mg / day.
Osteoarthritis: tablets are prescribed at the rate of 7.5 mg / day, suppositories - 15 mg / day (1 suppository). If necessary, the dose can be increased to 15 mg / day (2 tablets) 1 time per day.
Rheumatoid arthritis: prescribed at the rate of 15 mg / day. When a therapeutic effect is achieved, the dose can be reduced to 7.5 mg / day.

In patients with an increased risk of adverse reactions, the initial dose is 7.5 mg / day. In patients on dialysis with severe renal insufficiency, the dose should not exceed 7.5 mg / day. Since the risk of adverse reactions increases with increasing dose and duration of treatment, it is necessary to use the drug in the minimum effective daily dose and with the shortest possible duration of treatment.

Contraindications for use

It is forbidden to use this drug for people who have the following diseases:

active gastrointestinal bleeding, recent cerebrovascular bleeding or established diagnosis of diseases of the blood coagulation system;
concomitant therapy with anticoagulants, tk. there is a risk of intramuscular hematoma formation;
severe liver failure;
severe heart failure;
severe renal failure (if hemodialysis is not performed, QC<30 мл/мин, а также при подтвержденной гиперкалиемии);
active liver disease;
erosive and ulcerative lesions of the stomach and duodenum in the acute phase or recently transferred;
inflammatory bowel disease (Crohn's disease or ulcerative colitis in the acute phase);
therapy of perioperative pain during coronary artery bypass surgery;
pregnancy;
lactation period (breastfeeding);
age up to 18 years;
hypersensitivity to the active substance or auxiliary components of the drug.
hypersensitivity (including to other NSAIDs), complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose or paranasal sinuses, angioedema or urticaria caused by intolerance to acetylsalicylic acid or other NSAIDs (including history) due to existing likelihood of cross-sensitivity.

Carefully:

a history of gastrointestinal disease (presence of Helicobacter pylori infection);
congestive heart failure;
cerebrovascular diseases;
dyslipidemia/hyperlipidemia;
diabetes;
peripheral arterial disease;
renal failure (CC 30-60 ml / min);
elderly age;
prolonged use of NSAIDs;
smoking;
frequent use of alcohol;
concomitant therapy with the following drugs: anticoagulants, oral corticosteroids, antiplatelet agents, selective serotonin reuptake inhibitors.

Side effects

When using the drug, it is necessary to observe the dosage indicated in the instructions for use, otherwise the following adverse reactions may develop:

From the urinary system: edema, hypercreatininemia, increased urea concentration. In rare cases - interstitial nephritis, glomerulonephritis, renal medullary necrosis, nephrotic syndrome.
From the digestive system: nausea, vomiting, belching, abdominal pain, constipation or diarrhea, flatulence, increased activity of “liver” transaminases, hyperbilirubinemia, stomatitis, erosive and ulcerative lesions of the gastrointestinal tract, gastrointestinal bleeding (hidden or overt).
From the side of the cardiovascular system: increased blood pressure, flushes of blood to the skin of the face and upper chest, palpitations.
From the nervous system: dizziness, headache, drowsiness.
From the side of the hematopoietic organs: anemia, leukopenia, thrombocytopenia.
Allergic reactions: skin rash, itching, blisters.
Other: ringing in the ears.

As with the use of other non-steroidal anti-inflammatory drugs, during treatment with Movalis there is a possibility of developing nephrotic syndrome, glomerulonephritis, renal medullary necrosis and interstitial nephritis.

With the combined use of Movalis with drugs that depress the bone marrow (for example, with methotrexate), cytopenia may develop. Gastrointestinal bleeding, perforation, or ulcer associated with therapy can be fatal.

Overdose

In acute overdose of NSAIDs, the following symptoms may occur, which are usually reversible with maintenance therapy:

weakness, drowsiness, nausea, vomiting and epigastric pain, there may be gastrointestinal bleeding.

Severe intoxication can lead to hypertension, acute renal failure, liver failure, respiratory depression, coma, seizures, and cardiovascular failure. As well as in the treatment of NSAIDs, with their overdose, there may be anaphylactoid reactions.

Analogues

Many people are wondering: how to replace Movalis? One of the cheapest analogues of Movalis today are drugs: Mirloks, Artrozan, Melox, Meloxicam, Mataren.

Prices

The average price of MOVALIS injections in pharmacies (Moscow) is 580 rubles.

Storage conditions

Store in a cool, dark place. The maximum temperature at which the drug can be stored should not exceed 30 degrees. Shelf life 5 years.

Pharmacodynamics. Meloxicam is an NSAID of the enolic acid class that has anti-inflammatory, analgesic and antipyretic effects. Meloxicam exhibits high anti-inflammatory activity in all standard models of inflammation. The mechanism of action is due to the ability to inhibit the biosynthesis of prostaglandins - inflammatory mediators due to selective inhibition of COX-2, while providing a safer mechanism of action due to selective inhibition of COX-2 compared to COX-1. It has now been proven that the therapeutic effect of NSAIDs is associated with inhibition of COX-2 synthesis, while inhibition of COX-1 leads to side effects from the stomach and kidneys.
The selectivity of COX-2 inhibition by meloxicam has been confirmed by many researchers as in vitro, and ex vivo. Meloxicam (7.5 and 15 mg) predominantly inhibits COX-2 e x vivo, which is confirmed by a greater inhibition of PGE2 production in response to lipopolysaccharide stimulation compared with the production of thromboxane in coagulated blood (COX-1). These effects are dose dependent. Meloxicam does not affect platelet aggregation or bleeding time at recommended doses. ex vivo, while indomethacin, diclofenac, ibuprofen and naproxen significantly inhibit platelet aggregation and increase bleeding time.
In clinical studies, a low incidence of gastrointestinal side effects (perforation, ulceration and bleeding) was found with the use of meloxicam at recommended doses compared with standard doses of other NSAIDs.
Pharmacokinetics. Meloxicam is well absorbed in the gastrointestinal tract when administered orally; the absolute bioavailability of the drug is 89%. The simultaneous use of food does not affect the absorption of the drug. The concentration of the drug when taken orally 7.5 and 15 mg per day, respectively, is dose-dependent. A stable concentration is reached on the 3rd and 5th day.
Continuous treatment over a long period (eg 6 months) did not lead to changes in pharmacokinetic parameters compared with the parameters after 2 weeks of oral administration of meloxicam at a dose of 15 mg per day. Any changes are also unlikely with a duration of treatment of more than 6 months.
More than 99% of meloxicam binds to plasma proteins. The drug penetrates into the synovial fluid, its concentration there is 2 times lower than in the blood plasma.
After i / m injection, meloxicam is completely absorbed, which indicates its absolute bioavailability (almost 100%).
The pharmacokinetics of meloxicam is linear and dose-dependent when administered intramuscularly at doses of 7.5 and 15 mg. The concentration of meloxicam in plasma reaches a maximum 60 minutes after the intramuscular injection.
Meloxicam undergoes extensive biotransformation in the liver. Meloxicam is almost completely metabolized to 4 pharmacological inert metabolites. The main metabolite, 5-carboxymeloxicam (60% of the dose), is formed by oxidation of the intermediate metabolite 5-hydroxymethylmeloxicam, which is excreted to a lesser extent (9% of the dose). Research in vitro suggest that CYP 2C9 plays an important role in the metabolic process, CYP 3A4 - to a lesser extent. Peroxidase activity in patients is probably responsible for 2 other metabolites, which account for 16 and 4% of the dose received, respectively.
Excretion of meloxicam, mainly in the form of metabolites, is carried out in the same amount with urine and feces. Less than 5% of the daily dose is excreted unchanged in the feces, while only traces of the unchanged substance are excreted in the urine. The half-life is about 20 hours. Hepatic and renal insufficiency does not significantly affect the pharmacokinetics of meloxicam.
Plasma clearance is 8 ml/min. Clearance is reduced in older women. The volume of distribution is low, averaging 11 liters. Individual deviations are 30-40% after i / m application.

Indications for the use of the drug Movalis

Tablets, suppositories: symptomatic treatment of pain in osteoarthritis (arthrosis, degenerative joint diseases); rheumatoid arthritis; ankylosing spondylitis.
Injection solution: for the initial and short-term treatment of these same diseases.

The use of the drug Movalis

Tablets, suppositories
In adults
Osteoarthritis: tablets and suppositories are prescribed at the rate of 7.5 mg / day. If necessary, the dose can be increased to 15 mg / day (2 tablets or 1 suppository) 1 time per day.
Rheumatoid arthritis
Ankylosing spondylitis: prescribed at the rate of 15 mg / day. When a therapeutic effect is achieved, the dose can be reduced to 7.5 mg / day.
In patients with an increased risk of adverse reactions, the initial dose is 7.5 mg / day.
In patients on dialysis, with severe renal insufficiency, the dose should not exceed 7.5 mg / day.
Since the risk of adverse reactions increases with increasing dose and duration of treatment, it is necessary to use the drug in the minimum effective daily dose and with the shortest possible duration of treatment.
Adolescents over the age of 12: tablets and suppositories - the maximum recommended daily dose is 0.25 mg / kg.
The maximum recommended daily dose of Movalis is 15 mg.
Given that the dose for children has not been established, the use of the drug should be limited only to adolescents over 12 years of age and adults.
The tablet should be taken with food, without chewing, with water or other liquid.
Solution for injection: i / m application is advisable to appoint only during the first few days of treatment. In the future, oral forms of the drug should be used to continue treatment.
The recommended dose of Movalis for injection is 7.5 mg or 15 mg / day, depending on the intensity of pain and the severity of inflammation.
Since the risk of adverse reactions increases with increasing dose and duration of treatment, it is necessary to use the drug in the minimum effective daily dose with the shortest duration of treatment.
Movalis should be administered by deep intramuscular injection.
Given the possible incompatibility, Movalis in the form of an injection solution should not be mixed with other drugs in the same syringe.
In patients with severe renal insufficiency who are on dialysis, the dose should not exceed 7.5 mg / day.
Movalis in the form of an injection solution should not be administered intravenously.
Given that the dose regimen for children and adolescents under the age of 15 has not been established, the drug is recommended for the treatment of only adults and adolescents over 15 years of age.
Combined application: the total daily dose of Movalis when used in the form of tablets and suppositories should not exceed 15 mg.
The duration of the course of treatment depends on the nature of the disease and the effectiveness of the therapy.

Contraindications to the use of the drug Movalis

Known hypersensitivity to meloxicam or other components of the drug.
Movalis should not be administered to patients with symptoms of asthma, nasal polyps, angioedema, or a history of urticaria associated with the use of acetylsalicylic acid or other NSAIDs, since cross-hypersensitivity reactions are possible.
Also contraindications are:

active or newly diagnosed peptic ulcer/perforation of the gastrointestinal tract;
active inflammatory bowel disease (Crohn's disease or ulcerative colitis);
severe liver failure;
kidney failure that is not amenable to dialysis;
manifest gastrointestinal bleeding, recent cerebrovascular bleeding or other disorders accompanied by bleeding;
severe decompensated heart failure;
children under the age of 12 years - use in the form of tablets and suppositories;
children under the age of 15 - use as an injection solution;
During pregnancy and breastfeeding.

Movalis is contraindicated for the elimination of postoperative pain in coronary artery bypass grafting.
The use of the drug is contraindicated in the treatment of congenital malformations, in which the inactive components of the drug may be unsafe (see).

Side effects of Movalis

Some side effects have been reported that may occur with the use of Movalis. The information is based on clinical studies conducted in 3750 patients who took Movalis orally daily at a dose of 7.5-15 mg in the form of tablets for more than 18 months (mean duration of treatment - 127 days), and 254 patients who were administered Movalis in the form of r- ra for injection by intramuscular injection for 7 days.
From the gastrointestinal tract:
with a frequency of 1% - dyspepsia, nausea, vomiting, abdominal pain, constipation, diarrhea, flatulence; 0.1-1% - transient increase in liver function tests (increased activity of transaminases or serum bilirubin levels), belching, esophagitis, peptic ulcer of the stomach and / or duodenum, gastrointestinal bleeding); ≤0.1% - perforation of the wall of the digestive tract, colitis, hepatitis, gastritis.
Gastrointestinal bleeding, ulceration, or perforation can be potentially fatal.
From the hematopoietic system:
with a frequency of 1% - anemia; 0.1-1% - changes in the blood count, including the ratio of leukocytes, leukopenia and thrombocytopenia. The simultaneous use of a potentially myelotoxic drug, especially methotrexate, can lead to the development of cytopenia.
From the side of the skin:
with a frequency of more than 1% - itching, skin irritation; 0.1-1% - stomatitis, urticaria; ≤0.1% - photosensitivity. In some cases, polymorphic erythema, Stevens-Johnson syndrome, toxic epidermal necrolysis may develop.
From the respiratory system:
with a frequency of ≤1% - the occurrence of asthma attacks in people allergic to acetylsalicylic acid or other NSAIDs.
From the side of the central nervous system:
1% - slight dizziness, headache; 0.1-1% - tinnitus, lethargy; ≤0.1% - confusion and disorientation, mood changes.
From the side of the cardiovascular system:
1% - edema; 0.1-1% - increased blood pressure, hot flashes, palpitations.
From the genitourinary system:
0.1-1% - change in indicators of kidney function (increased levels of creatinine and / or blood urea); ≤0.1% - OPN.
The use of NSAIDs may be accompanied by impaired urination, including acute urinary retention.
From the side of the organ of vision:
≤0.1% - conjunctivitis, impaired visual function, (blurred vision).
Hypersensitivity reactions:
≤0.1% of cases - angioedema and immediate hypersensitivity reactions, as well as anaphylactoid / anaphylactic reactions, including anaphylactic shock.
Violation at the site of application:
more often than 1%: hematoma at the injection site; 0.1-1% - pain at the injection site.

Special instructions for the use of the drug Movalis

When using the drug Movalis, like other NSAIDs, it is necessary to strictly monitor patients with gastrointestinal diseases and patients taking anticoagulants. Patients with gastrointestinal pathology should be under strict control. In the presence of peptic ulcer or gastrointestinal bleeding, Movalis is contraindicated.
As with other NSAIDs, potentially fatal gastrointestinal bleeding, peptic ulcer or perforation may occur at any time during treatment with or without prior symptoms or a history of severe gastrointestinal disease. The most serious consequences of the use of the drug were noted in the elderly.
Serious skin reactions, some of them fatal, have been reported with NSAIDs in very rare cases, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The highest risk of such reactions was noted at the beginning of treatment, while in most cases such reactions appeared in the first month of treatment. At the first appearance of a skin rash, lesions of the mucous membranes or other signs of hypersensitivity, Movalis should be discontinued.
NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction and stroke (including fatal). With increasing duration of treatment, this risk increases. This risk may be increased in patients with cardiovascular disease or risk factors for such disease.
NSAIDs inhibit the synthesis of renal prostaglandins, which plays an important role in maintaining renal blood flow. In patients with reduced BCC and renal blood flow, the use of NSAIDs can cause the development of reversible renal failure, which disappears after discontinuation of the drug.
The highest risk of this reaction is noted in elderly patients, patients with dehydration, congestive heart failure, cirrhosis of the liver, nephrotic syndrome and chronic kidney disease, as well as those taking diuretics, ACE inhibitors or angiotensin-II receptor antagonists, or in patients after major surgery leading to hypovolemia. Such patients need to control diuresis and kidney function at the beginning of therapy.
Rarely, the use of NSAIDs can lead to the development of interstitial nephritis, glomerulonephritis, renal medullary necrosis, or nephrotic syndrome.
As with most NSAIDs, isolated cases of elevated transaminases or other indicators of liver function have been reported. Most of these changes were minor and transient. With a persistent and significant deviation of these indicators from the norm, treatment with Movalis should be discontinued and a follow-up study should be carried out. With a clinically stable course of liver cirrhosis, there is no need to reduce the dose of Movalis.
Debilitated patients need more careful monitoring, as they are more difficult to tolerate side effects. As with other NSAIDs, caution should be exercised when prescribing to elderly patients who are more likely to have decreased renal, hepatic, and cardiac function.
When using NSAIDs, there may be a delay in sodium, potassium and water in the body and an effect on the natriuretic effect of diuretics. As a result, symptoms of heart failure or hypertension (arterial hypertension) may occur or worsen in hypersensitive individuals, therefore careful clinical observation is recommended in high-risk patients.
Meloxicam, like any other NSAID, can mask the symptoms of infectious diseases.
The use of meloxicam, as well as other drugs that inhibit the synthesis of COX / prostaglandins, can damage the fertilization process and that is why it is not recommended for women who plan to become pregnant. Moreover, women who have fertility problems or who are undergoing investigation for infertility should consider discontinuing meloxicam.
During pregnancy and breastfeeding. Despite the fact that no teratogenic effect was detected during preclinical studies, Movalis should not be used during pregnancy and lactation.
Influence on the ability to drive vehicles or work with other mechanisms. It has not been identified, however, with the development of such side effects as impaired visual function, drowsiness or other disorders of the central nervous system, it is recommended to temporarily refrain from such activities.

Movalis drug interactions

Other prostaglandin synthetase inhibitors, including corticosteroids and salicylates (acetylsalicylic acid): the simultaneous administration of prostaglandin synthetase inhibitors due to their synergistic effect may lead to an increase in ulcerogenic action and the risk of bleeding, therefore such combined treatment is not recommended. Meloxicam should not be co-administered with other NSAIDs.
Oral anticoagulants, antiplatelet agents, systemic heparin, thrombolytic agents, and selective serotonin reuptake inhibitors: increased risk of bleeding due to decreased platelet function. If it is not possible to avoid the simultaneous use of Movalis with the drugs listed above, careful monitoring of the blood coagulation system is necessary.
Lithium: there is evidence regarding the ability of NSAIDs to increase the concentration of lithium in the blood. It is recommended to monitor the content of lithium in the blood plasma at the beginning of treatment, when selecting a dose and in the event of discontinuation of treatment with Movalis.
Methotrexate: like other NSAIDs, Movalis can increase the hematological toxicity of methotrexate, which requires serious monitoring when prescribing this combination.
Contraceptives: NSAIDs can reduce the effectiveness of hormonal birth control.
Diuretics: the appointment of NSAIDs to patients with dehydration can lead to a potential risk of developing acute renal failure, therefore, before starting treatment, disturbances in the water and electrolyte balance should be eliminated, and in the future, with the simultaneous appointment of Movalis and diuretics, patients should consume an adequate amount of fluid.
Antihypertensive drugs(for example, β-adrenergic receptor blockers, ACE inhibitors, vasodilators, diuretics): the effectiveness of antihypertensive drugs (β-adrenergic receptor blockers, ACE inhibitors, vasodilators, diuretics) decreases when used simultaneously with NSAIDs, which is associated with an inhibitory effect on vasodilator prostaglandins.
NSAIDs and angiotensin II receptor antagonists, as well as ACE inhibitors, have a synergistic effect on the reduction of glomerular filtration rate. In patients with impaired renal function, this can lead to the development of acute renal failure.
Colestyramine binds meloxicam in the digestive tract.
NSAIDs increase the nephrotoxicity of cyclosporine due to the effect on the synthesis of prostaglandins in the kidneys, which requires monitoring of kidney function while prescribing drugs.
Meloxicam is almost completely eliminated by hepatic metabolism, approximately two thirds of which occur with the participation of cytochrome P450 and one third by peroxidase oxidation.
Potential interactions should be taken into account with the simultaneous use of meloxicam and agents that inhibit or are metabolized by CYP 2C9 and / or CYP 3A4. Perhaps the pharmacokinetic interaction of Movalis and other drugs at the stage of metabolism due to their effect on CYP 2C9 and / or CYP 3A4.
Pharmacokinetic interaction of Movalis with antacids, cimetidine, digoxin and furosemide with simultaneous use has not been identified.
It is impossible to exclude the possibility of interaction of the drug with oral hypoglycemic agents.

Movalis overdose, symptoms and treatment

Movalis storage conditions

In a place protected from light at a temperature not exceeding 25 ° C.

List of pharmacies where you can buy Movalis:

St. Petersburg

average rating

Based on 0 reviews

Movalis is a non-steroidal anti-inflammatory drug (NSAID) that, when administered, has analgesic, antipyretic, and anti-inflammatory effects. Injections are often prescribed at the very beginning of treatment, when the inflammatory and pain syndromes are more pronounced. After alleviating the patient's condition, therapy is continued with rectal suppositories or oral tablets. The duration of the course of treatment is determined by the doctor.

In this article, we will consider in detail the instructions for using the drug in injectable form, i.e., in injections, including such questions: for what symptoms should it be used, how many days and how often can the medicine be injected and how to do it correctly, can it be used with other drugs.

Compound

active ingredient - meloxicam (15 mg);
additional substances - glycofurfurol, meglumine, poloxamer 188, sodium chloride, sodium hydroxide, glycine, distilled water.

Indications for use

Movalis is an injection solution that is recommended for patients with pronounced pain in joint diseases, diseases of the spine and musculoskeletal system. In addition, it is indicated for the short-term symptomatic treatment of diseases such as:

arthritis;
gonarthrosis;
ankylosing spondylitis;
it is also widely used in neurology for various and pinched nerves.

Application and dosage

Movalis is used as an intramuscular injection, it should be injected deep into the gluteal muscle. If there are no other appointments of a specialist, then the daily dose of the drug is 7.5-15 mg. Due to the long action, Movalis can be used once every 24 hours. The duration of therapy should not exceed 3 days. After the specified period, it is recommended to take the drug in the form of tablets or suppositories.

Contraindications

Movalis is contraindicated in people with intolerance to the active or one of the additional substances.
It is not recommended for use by persons with high sensitivity to acetylsalicylic acid, erosive and ulcerative lesions of the digestive tract, women during childbearing and lactation.
Prohibited in patients with severe renal failure without hemodialysis.
Movalis is not recommended for persons under 14 years of age due to insufficient knowledge of the effect of the drug on the children's body.
Movalis should not be used in patients with bronchial asthma, functional pathologies of the hematopoietic organs and with compensated heart failure.
It is prescribed with caution to persons who have previously experienced side effects while taking other NSAIDs, such as urticaria, nasal mucosal polyps, angioedema, as well as patients with a history of gastrointestinal diseases, cerebrovascular diseases, diabetes mellitus, smokers and people who drink alcohol frequently.

Overdose

There are very few data on drug overdose. However, presumably, with a significant excess of the dosage of the drug, symptoms may develop that are characteristic of an overdose of other non-steroidal anti-inflammatory drugs.

Ask your question to a neurologist for free

Irina Martynova. Graduated from the Voronezh State Medical University. N.N. Burdenko. Clinical intern and neurologist of BUZ VO \"Moscow Polyclinic\".

drowsiness;
confusion;
disorders of the digestive system;
pain in the epigastric region;
bleeding in the gastrointestinal tract;
jumps in blood pressure;
functional disorders of the respiratory system (up to the absence of breathing);
kidney failure;
heart failure.

Therapeutic measures: in case of an overdose of the drug and the occurrence of subsequent symptoms, it is urgently removed from the body.

Side effects

If injection therapy is carried out according to the doctor's prescription, and the dosage of the drug does not exceed the permissible rate, side effects rarely occur. But still, given the individual characteristics of each patient, among the side effects can be identified:

functional disorders of the digestive system, the development of ulcers of the mucous membranes of the digestive tract, functional disorders of the hematopoietic organs;
the occurrence of anemia, a significant decrease in the blood level of platelets and leukocytes;
development of bronchial asthma;
the appearance of migraine, light and sound fear, dizziness, congestion and tinnitus, confusion, depression;
the occurrence of tachycardia (increased heart rate), increase / decrease in blood pressure, swelling of the lower and upper extremities;
a significant decrease in vision, conjunctivitis;
allergic reactions in the form of a skin rash;
with prolonged use of injections, necrosis (necrosis) of muscle tissue may develop.

Expert opinion

Mitrukhanov Eduard Petrovich

Doctor - neurologist, city polyclinic, Moscow. Education: Russian State Medical University, Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation, Volgograd State Medical University, Volgograd.

Movalis may cause a decrease in the rate of reaction. During the treatment period, you should not drive or engage in activities that require increased attention.

Interaction with other drugs

With the simultaneous use of Movalis and another non-steroidal drug, for example, the risk of developing ulcers of the mucous membranes of the digestive tract, as well as gastrointestinal bleeding, increases.
With the combined use of Movalis with potentially myelotoxic drugs, there is a possibility of developing a deficiency of one or more types of blood cells (cytopenia).
Movalis, like other medications of the NSAID group, significantly reduces the effectiveness of intrauterine contraception.
In patients with obvious dehydration during the period of NSAID use, acute renal failure may develop. Simultaneous use of Movalis with diuretics should be accompanied by abundant fluid intake.
Due to a decrease in the rate of synthesis of prostaglandin-vasodilators, Movalis reduces the effectiveness of acetylcholinesterase inhibitors, diuretics, and beta-blockers.
Colestyramine contributes to the accelerated excretion of the active substance Movalis from the body.
With a simultaneous introduction of Movalis and Cyclosporine into the body, the nephrotoxicity of the latter is significantly enhanced, therefore, when they are taken simultaneously, monitoring of kidney function is necessary.
Meloxicam contributes to the retention of potassium, sodium, fluid in the patient's body and reduces the effect of saluretic diuretics, as a result of which hypertension and heart failure may progress in the patient.
Due to lack of compatibility data Movalis solution should not be mixed in the same syringe with any other injection solutions.

Why is Movalis better?

According to numerous reviews of patients and specialists, Movalis is recognized as a highly effective drug that is well tolerated by the body. The analgesic and anti-inflammatory effect of Movalis, in comparison with other drugs of the non-steroidal group, is much higher, and the effect is longer. In addition, the drug does not have a destructive effect on cartilaginous tissues, which excludes the possibility of further formation of metabolic joint diseases, such as arthrosis. This is the absolute advantage of Movalis over other NSAIDs prescribed for diseases of the joints and spine. This medication is not prescribed in exceptional cases in the presence of contraindications.

Expert opinion

Filimoshin Oleg Alexandrovich

Doctor - neurologist, city polyclinic of Orenburg. Education: Orenburg State Medical Academy, Orenburg.

Patients with severe renal insufficiency who are on dialysis may use the drug at a dose not exceeding 7.5 mg / 24 hours.
For patients with moderate renal insufficiency, the recommended daily dose, as in other cases, is 15 mg / 24 hours.

Produced in the form of a solution for injection, it is convenient because, due to its rapid absorption into the blood and long-term action, it can be used once every 24 hours.

Unlike the tablet form of the drug, injections are produced in ampoules of a single volume, which facilitates the calculation of the administered dosage.

Price

The average price of a medicine both in injections for intramuscular injection and in tablets in the territory of the Russian Federation is 650-700 rubles.

Holiday conditions

The drug in the form of a solution for injection is dispensed by prescription of a specialist.

Storage conditions

Ampoules are stored in a place protected from direct sunlight, at a temperature not exceeding +25 degrees. After opening the ampoule, the solution cannot be stored.

Shelf life

The expiration date of the drug is indicated both on the original packaging and on the ampoule itself and is 5 years from the date of manufacture.

Analogues

Medical preparations similar in composition, also used in the form of injections (prices are indicated for 3 ampoules):

- from 200 rubles.
— from 250 r.
— from 390 r.
Bi-xicam — from 160 rubles.

If you decide to use analogues of the drug, this decision should be discussed with your doctor! Remember: the dosage, frequency of administration and the analogue itself must be selected by a specialist in accordance with the individual characteristics of the patient's body! Self-medication is unacceptable!

Selective anti-inflammatory agent. Stops the pathological process directly in the focus of inflammation and causes fewer side effects than other drugs of the NSAID group. It is used as a means of symptomatic therapy, mainly in rheumatological diseases. Contraindicated in patients under 18 years of age.

Dosage form

The drug Movalis is a product of the pharmaceutical company Boehringer Ingelheim (Austria). Available in several dosage forms:

Tablets 7.5 mg and 15 mg.
Rectal suppositories 7.5 mg and 15 mg.
Injections for injections in 1.5 ml ampoules.
Suspension for oral administration.

The choice of dosage form always remains with the attending physician, who will be able to choose the dose of the drug depending on the severity of the disease, the diagnosis, and the characteristics of the patient's body.

Description and composition

Movalis is a non-steroidal anti-inflammatory drug based on. The drug is often used in the treatment of degenerative-dystrophic diseases affecting the human musculoskeletal system. The main principle of action of the drug is to relieve pain, reduce the inflammatory process. Movalis is a drug from the group of phenolic acids. The drug is often used in the treatment of diseases such as rheumatoid arthritis, osteoarthritis, osteochondrosis and others. Based on the reviews that are left on various forums, we can conclude that Movalis is one of the effective drugs, but at the same time it has many contraindications, so it must be used correctly and only as directed by a doctor.

Pharmacological group

Movalis from the group of non-steroidal anti-inflammatory drugs has a pronounced anti-inflammatory, analgesic and antipyretic properties. It is often used to treat inflammatory diseases. The properties of the drug are due to its composition, which contains. This component reacts with prostaglandins, thereby eliminating pain and inflammation.

Movalis belongs to a new generation of drugs, has a smaller list of contraindications, but is not inferior to analogues in terms of effectiveness. The advantage of the drug is that this drug belongs to COX-2 inhibitors, which allows it not to have any negative effect on the body, to act only in the area of inflammation. Unlike other similar drugs from the group of non-steroids, Movalis inhibits platelet aggregation.

Indications for use

The medicine Movalis can be used in almost all diseases of the musculoskeletal system, which are accompanied by pain and inflammation.

For adults

The main indications for the appointment of the drug may be the following diseases:

osteoarthritis;
osteochondrosis of the cervical, thoracic or lumbar spine;
ankylosing spondylitis;
rheumatoid arthritis.

Other diseases with severe pain syndrome may also be an indication for the use of the drug.

For kids

Movalis is contraindicated in children under 14 years of age, therefore, there is no information about the indications, as well as the doses of the drug, in the instructions.

During pregnancy, the drug Movalis in any form of release and doses is contraindicated. Moreover, taking this drug can provoke pathologies in the development of the fetus, provoke a miscarriage in the early stages or premature birth in the late trimesters.

Contraindications

Movalis is a potent drug, so it has a fairly wide list of contraindications.

heart failure;
bronchial asthma;
composition intolerance;
ulcerative lesions of the intestine;
age up to 14 and after 80 years;
period of pregnancy.

Applications and doses

The drug Movalis can only be prescribed to adults and only to those who have no contraindications to it. In the acute period of the disease, the doctor may prescribe injections with the drug, a course of 3-4 days. When the pain decreases, the patient can switch to tablets or rectal suppositories.

After an intramuscular or intravenous injection, the effect of the drug is noted after 30 minutes and lasts for 6 hours. Regardless of the diagnosis, stage of the disease and symptoms, the daily dose of the drug should not exceed 7.5 - 15 mg.

For adults

Doses of the drug are set by the doctor individually for each patient.

Ampoules for injection are prescribed only 1 time per day at a dose of 7.5 or 15 mg. The dose is set by the attending physician. The duration of admission is 2-3 days, then the patient is transferred to tablets or suppositories.
Movalis tablets can be used 2 times a day for 7.5 or 15 mg.
Suppositories of the drug are injected into the rectum at bedtime 1 time per day.

The average treatment course is 10 - 28 days.

For kids

For pregnant women and during lactation

During pregnancy, as well as during lactation, the drug can not be used.

Side effects

Movalis has a fairly large list of contraindications, but all of them are too rare and only if the recommended doses of the drug are not observed or if there is a history of contraindications. In practice, the most common side effects are:

violation of the heart rhythm;
headache;
nausea, ;
skin rash;
jumps in blood pressure;
limb swelling.

Patient complaints about such symptoms are the reason for discontinuing the drug or reducing the dose of the drug.

Interaction with other drugs

Co-administration of Movalis with other drugs can give an undesirable reaction of the body, so if the patient is taking any other medications, this should be reported to the doctor.

Taking diuretics and Movalis increases the risk of developing kidney failure or dehydration.

special instructions

Persons with a history of severe diseases of the gastrointestinal tract, kidneys, liver or heart can take the drug in the minimum dosage and only under the supervision of medical specialists.
With prolonged use of the drug, you need to monitor the function of the kidneys and liver, take laboratory tests of urine and blood.

Analogues

Instead of Movalis, you can use the following medicines:

is a complete analogue of the drug Movalis. In a pharmacy, the drug is available in injections, tablets and suppositories. It can be prescribed to patients older than 15 years. contraindicated in women in position and breastfeeding, as well as in patients planning to conceive.
Artrum refers to non-steroidal anti-inflammatory drugs. As an active ingredient, the drug contains. On sale it happens in prolonged tablets, gel, suppositories, injection solution. The drug is taken for pathologies of the musculoskeletal system of an inflammatory and degenerative nature, for the relief of pain of various origins. Artrum can be prescribed to patients who are 15 years old, including in the I and II trimester of pregnancy.
refers to Movalis substitutes in the therapeutic group. As an active ingredient, the drug contains. In a pharmacy, the medicine comes in the form of regular and dissolving tablets, oral suspensions, and gels. The drug can be prescribed to children whose weight has reached 7 kg.
contains as an active component. The drug is available in rectal suppositories, gel, injections, transdermal patches, tablets. The drug is recommended as an analgesic for pathologies of the locomotor system, for hepatic and renal colic, migraine pain, after injuries and surgical treatment. According to strict indications, it can be used up to.

Overdose

If the prescribed doses of the drug are not observed, there is a high risk of developing overdose symptoms:

nausea, ;
fainting state;
drowsiness;
increased risk of intestinal bleeding.

When these symptoms appear, you should seek medical help as soon as possible.

Storage conditions

When storing the drug, you need to limit the access to light and sunlight. The optimum temperature of the drug is 25 degrees. The shelf life of the drug is indicated on the package, is 5 years from the date of issue.

Price

The cost of the drug is an average of 677 rubles. Prices range from 452 to 1150 rubles.